1. Abstract 14975: Transitioning Parenteral Prostacyclin Analogs to Selexipag in Pulmonary Arterial Hypertension.
- Author
-
Shelburne, Nicholas J, Parikh, Kishan S, Kennedy, Karla, Dahhan, Talal, Fortin, Terry, and Rajagopal, Sudarshan
- Subjects
- *
PULMONARY hypertension , *PROSTACYCLIN , *PARENTERAL therapy , *ACADEMIC medical centers , *INTRAVENOUS therapy - Abstract
Introduction: Selexipag, an oral selective prostacyclin receptor agonist, delays disease progression versus placebo in pulmonary arterial hypertension (PAH). In appropriate patients, transitioning from parenteral prostacyclin analogs to selexipag may alleviate the risks associated with long-term parenteral therapy. We report our experience with the feasibility, safety and challenges associated with systematic transition from parenteral prostacyclin therapy to selexipag in compensated PAH. Methods: From Jan. 2016 to July 2017, patients with PAH at Duke University Medical Center who were stable on parenteral prostacyclin therapy were offered the opportunity to transition to selexipag via standardized protocol. Patients underwent pre- and post-transition assessments of hemodynamics, echocardiography, biomarkers, and functional status. Patient demographics, clinical characteristics and any adverse effects were recorded in a database. Data are presented as median (Q1, Q3) unless specified. Results: Overall, 14 patients (11 women; age 53 years (48, 59); BMI 30.1 kg/m2 (26.9, 33.2)) were included with median follow-up of 5.5 months (4.1, 6.4). Of these, 13 patients tolerated the transition to selexipag and remained on drug (total daily dose 3200 mcg (3200, 4800)) at study completion. Two patients required an additional PAH medication during and after the transition period. Overall, pre- and post-transition NT-proBNP, 6MWD, TAPSE, RV function, and hemodynamics were stable (Table 1). The patient who failed the switch as assessed by worsening symptoms and surrogate markers had portopulmonary hypertension with intravenous therapy complicated by catheter-associated infection prior to the switch. Conclusions: The transition from parenteral prostacyclin therapy to selexipag was generally well tolerated in patients with compensated PAH. Our results support further study of the long-term implications of this transition in appropriate patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018